To our knowledge only a single study has examined the impact of the CYP2D6 phenotype on breast cancer prevention with tamoxifen, and no association between the CYP2D6 phenotype and ER-positive breast cancer occurrence was observed [51]. Here, CYP2D6 is linked to breast cancer.